Telehealth Platforms Truemeds Raises $22 million in a Series B Round of Funding The company plans to utilize the funds to accelerate growth in the untapped domestic market and expand its coverage across the country

By Akshit Pushkarna

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Truemeds' Founders Akshat Nayyar and Dr. Kunal Wani

Telehealth platform Truemeds announced that they have raised $22 million in its series B funding round. The funding was led by private equity fund Westbridge Capital and also saw participation from existing investors InfoEdge Ventures, Asha Impact and IAN Fund. The round witnessed oversubscription from new and existing investors however the company decided to cap the raise to $22 million.

Founded by Ex-Abbott executives, Akshat Nayyar and Dr.Kunal Wani, Truemeds was founded in 2019 and is headquartered in Mumbai. The company last raised $5 million in a Series A funding round back in June, 2021. Truemeds plans to utilize the funds to accelerate growth in the untapped domestic market and expand its coverage across the country.

The telehealth industry, of which Truemeds is a key player, is expected to enjoy a significant growth in business in the coming years. A Statista report released in 2020 predicted the industry to generate revenue a total revenue of $5.5 billion by 2025. The company has seen a good growth in demand owed to its proprietary algorithm and tele-consultation, through which they are able to recommend best value medicines to customers with precise scientific matching.

India is one of the very few markets where Truemeds has pseudo-categorisation of medicines in branded and generic-generic to create different price tiers between them. 95 percent of the drugs sold in India are off-patent (thus technically generics). There is absolutely no difference in the scientific composition of generics and branded drugs.

This market is growing at 1.5 times the overall pharmaceutical market and following the US landscape where the generics prescription share moved from 40% in 2005 to over 85 percent in 2019. The market move towards generics is inevitable, Truemeds co-founder Akshat Nayyar believes, and he believes his company will lead that change.

Commenting on the development, Nayyar said, "We are overwhelmed by the confidence our incoming and existing investors have shown in us. We are excited to welcome Westbridge Capital to join us as we make Truemeds a household name."

Sandeep Singhal, Managing Director, Westbridge Capital, commented, "We are excited to partner with Truemeds as they create value for patients by delivering high quality drugs at extremely affordable prices at the patients' doorstep. The founding team's strong category understanding has resulted in the success at Truemeds and we are excited to help take the company to the next level."

Akshit Pushkarna

Features Writer

Related Topics

Money & Finance

What Is a Tariff? Here's an Overview of the Basics.

Keep reading this article to discover the world of tariffs, their impact on global trade and their role in international relations.

Business Plans

12 Reasons You Need a Business Plan

In the new book "Write Your Own Business Plan," business expert Eric Butow breaks down how a solid business plan can save your startup during those tough early days.

Business News

Black Mirror's 'Joan Is Awful' Sparks Real-Life Worry Over Netflix's Terms and Conditions

Google searches for Netflix's terms and conditions spiked following the release of Black Mirror season 6.

Growing a Business

A 5-Time Founder Shares His Best Success Tips

Godard Abel's sold businesses to Oracle and Salesforce, and these are the three biggest secrets to his success.

News and Trends

Akasa Air: Is There a Change In Its Employee Centric Approach?

Akasa Air is suing pilots who resigned to join a rival airline without serving their notice period. However, the Federation Of Indian Pilots (FIP) emphasized that the relief sought by airline which aims to enforce the CAR against employees who violated the terms of their employment contracts, is not valid

Science & Technology

ChatGPT: What Is It and How Does It Work?

ChatGPT is the latest development in commercial AI technology. Keep reading to find out what ChatGPT is and how it works.